Codexis (CDXS) Q3 2024 earnings summary

Executive summary

• Q3 2024 revenues increased 38% year-over-year to $12.8 million, driven by strong product revenue growth and new customer collaborations in pharma manufacturing and siRNA assets.

• Net loss narrowed to $20.6 million from $34.9 million in Q3 2023, with improved operating expenses and margin expansion.

• Strengthened balance sheet with $31 million capital raise via ATM and new debt financing, extending cash runway into 2027.

• Enhanced leadership with new CFO and CTO appointments, and divested legacy genomics enzyme portfolio to focus on core business and ECO Synthesis™ platform.

• Out-licensed genomics enzyme portfolio to Alphazyme, with potential for milestone and royalty payments.

Financial highlights

• Q3 2024 total revenue was $12.8 million, with product revenue at $11.2 million and R&D revenue at $1.7 million.

• Product gross margin improved to 61% from 58% in Q3 2023.

• Net loss was $20.6 million ($0.29/share), improved from $34.9 million ($0.50/share) year-over-year.

• Cash, cash equivalents, and investments totaled $90.3 million as of September 30, 2024.

• Operating expenses decreased 29% year-over-year, reflecting lower R&D and absence of prior-year restructuring charges.

Outlook and guidance

• Reiterated 2024 guidance: total revenue of $56M–$64M, product revenue of $38M–$42M, R&D revenue of $18M–$22M, and product gross margin of 58%–63%, excluding PAXLOVID-related sales.

• Path to profitability targeted by end of 2026, with positive cash flow expected and operations funded into 2027.

• Early commercial licenses for ECO Synthesis™ platform anticipated in 2025, with full commercial launch in 2026.

• Anticipates slight increase in R&D expenses due to ECO Synthesis Innovation Lab investment.

• Focus in 2025 on scaling the ECO Synthesis innovation lab and increasing customer adoption.